Information Collection; Payments, 16268-16269 [2019-07816]

Download as PDF 16268 Federal Register / Vol. 84, No. 75 / Thursday, April 18, 2019 / Notices 20190338 ...... 20190360 ...... G G Greenbriar Equity Fund IV, L.P.; BDP International, Inc.; Greenbriar Equity Fund IV, L.P. Altair Engineering Inc.; Datawatch Corporation; Altair Engineering Inc. 11/28/2018 20190296 ...... 20190327 ...... 20190329 ...... G G G KK GP; Agnaten SE; KK GP. William Goldring; Diageo plc; William Goldring. Vista Equity Partners Fund VI, L.P.; Apptio, Inc.; Vista Equity Partners Fund VI, L.P. 11/29/2018 20190311 20190312 20190336 20190339 20190345 20190212 20190332 20190347 20190350 20190351 20190352 20190353 20190355 20190357 20190359 20190367 20190375 20190377 20190388 20190389 ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... G G G G G G G G G G G G G G G G G G G G 20190390 ...... 20190396 ...... G G IFM Global Infrastructure Fund; Vitol Holding B.V.; IFM Global Infrastructure Fund. Vitol Investment Partnership II Limited; VJVCo; Vitol Investment Partnership II Limited. Hexagon Composites ASA; AFS Holdco, LLC; Hexagon Composites ASA. Arcosa, Inc.; H.I.G. Capital Partners IV, L.P.; Arcosa, Inc. Audax Private Equity Fund V–A, L.P.; 3RC/Phoenix Investment, LLC; Audax Private Equity Fund V–A, L.P. Golden Gate Capital Opportunity Fund. L.P.; VeriSign, Inc.; Golden Gate Capital Opportunity Fund. L.P. Richard A. Robinson & Betti G. Robinson; O’Neal Industries, Inc.; Richard A. Robinson & Betti G. Robinson. China National Chemical Corporation; Bonide Products, Inc.; China National Chemical Corporation. AIA Oratam Sidecar LLC; Hudson Transmission Partners, LLC; AIA Oratam Sidecar LLC. Mr. Cooper Group Inc.; Evan M. Stone; Mr. Cooper Group Inc. Sun Capital Partners VI, LP.; Southfield Tier One Investment LP; Sun Capital Partners VI, LP. Chesapeake Energy Corporation; WildHorse Resource Development Corporation; Chesapeake Energy Corporation. Leggett & Platt Incorporated; Elite Comfort Solutions LP; Leggett & Platt Incorporated. Sentinel Capital Partners VI, L.P.; Irving Place Capital Partners III SPV, L.P.; Sentinel Capital Partners VI, L.P. Linden Capital Partners IV–A LP; Arlington Capital Partners III, L.P.; Linden Capital Partners IV–A LP. Sycamore Partners III, L.P.; Newell Brands Inc.; Sycamore Partners III, L.P. Klaus-Michael Kuhne; The Resolute Fund III, L.P.; Klaus-Michael Kuhne. Chatchaval Jiaravanon; Meredith Corporation; Chatchaval Jiaravanon. AIPCF VI Indirect Investor AIV LP; Armstrong Flooring, Inc.; AIPCF VI Indirect Investor AIV LP. American Industrial Partners Capital Fund V, L.P.; Elkay Manufacturing Company; American Industrial Partners Capital Fund V, L.P. Open Text Corporation; LiaisonTechnologies, Inc.; Open Text Corporation. Prime Communications, L.P.; GameStop Corp.; Prime Communications, L.P. FOR FURTHER INFORMATION CONTACT: Theresa Kingsberry, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC–5301, Washington, DC 20024, (202) 326–3100. By direction of the Commission. April J. Tabor, Acting Secretary. [FR Doc. 2019–07735 Filed 4–17–19; 8:45 am] BILLING CODE 6750–01–P DEPARTMENT OF DEFENSE GENERAL SERVICES ADMINISTRATION NATIONAL AERONAUTICS AND SPACE ADMINISTRATION [OMB Control No. 9000–0070; Docket No. 2019–0003; Sequence No. 18] Information Collection; Payments Department of Defense (DOD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA). ACTION: Notice and request for comments. jbell on DSK30RV082PROD with NOTICES AGENCY: In accordance with the Paperwork Reduction Act of 1995 and the Office of Management and Budget SUMMARY: VerDate Sep<11>2014 17:37 Apr 17, 2019 Jkt 247001 (OMB) regulations, the FAR Council invites the public to comment upon a renewal regarding advanced payments. DATES: Submit comments on or before: June 17, 2019. ADDRESSES: The FAR Council invites interested persons to submit comments on this collection by either of the following methods: • Federal eRulemaking Portal: This website provides the ability to type short comments directly into the comment field or attach a file for lengthier comments. Go to http:// www.regulations.gov and follow the instructions on the site. • Mail: General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405. ATTN: Ms. Mandell/IC 9000–0070, Payments. Instructions: Please submit comments only and cite Information Collection 9000–0070, Payments, in all correspondence related to this collection. Comments received generally will be posted without change to http:// www.regulations.gov, including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check www.regulations.gov, approximately two-to-three days after submission to verify posting (except allow 30 days for posting of comments PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 submitted by mail). This information collection is pending at the FAR Council. Mr. Kevin Funk, Procurement Analyst, at telephone 202–357–5805, or via email at kevin.funk@gsa.gov. SUPPLEMENTARY INFORMATION: FOR FURTHER INFORMATION CONTACT: A. Solicitation of Public Comment Written comments and suggestions from the public should address one or more of the following four points: (1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. E:\FR\FM\18APN1.SGM 18APN1 Federal Register / Vol. 84, No. 75 / Thursday, April 18, 2019 / Notices B. Purpose Firms performing under Federal contracts must provide adequate documentation to support requests for payment under these contracts. The documentation may range from a simple invoice to detailed cost data. The information is usually submitted once, at the end of the contract period or upon delivery of the supplies or services, but could be submitted more often depending on the payment schedule established under the contract (see Federal Acquisition Regulation (FAR) 52.232–1 through FAR 52.232–4, FAR 52.232–6, 52.232–7, and 52.232–10). jbell on DSK30RV082PROD with NOTICES C. Annual Reporting Burden Respondents: 1,724,163. Responses per Respondent: 6. Annual Responses: 10,344,978. Hours per Response: 0.25. Total Burden Hours: 2,586,245. Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405, at 202–501–4755. Please cite OMB Control No. 9000–0070, Payments, in all correspondence. Dated: April 15, 2019. Janet Fry, Director, Federal Acquisition Policy Division, Office of Governmentwide Acquisition Policy, Office of Acquisition Policy, Office of Governmentwide Policy. [FR Doc. 2019–07816 Filed 4–17–19; 8:45 am] BILLING CODE 6820–EP–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2019–N–1020] Aurolife Pharma, LLC, et al.; Withdrawal of Approval of 31 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA or Agency) is withdrawing approval of 31 abbreviated new drug applications (ANDAs) from SUMMARY: 16269 multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. Approval is withdrawn as of May 20, 2019. DATES: FOR FURTHER INFORMATION CONTACT: Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993–0002, 240–402–7945, Trang.Tran@fda.hhs.gov. The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. SUPPLEMENTARY INFORMATION: Application No. Drug Applicant ANDA 070470 ............... ANDA 070471 ............... ANDA 070531 ............... Disopyramide Phosphate Capsules USP, Equivalent to (EQ) 100 milligrams (mg) base. Disopyramide Phosphate Capsules USP, EQ 150 mg base ................ Clofibrate Capsules USP, 500 mg ........................................................ ANDA 070797 ............... ANDA 070956 ............... Chlorpheniramine Maleate Extended-Release Capsules USP, 12 mg Diazepam Tablets USP, 10 mg ............................................................ ANDA 071128 ............... Haloperidol Tablets USP, 0.5 mg ......................................................... ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ............... ............... ............... ............... ............... ............... ............... ............... ............... Haloperidol Tablets USP, 1 mg ............................................................ Haloperidol Tablets USP, 20 mg .......................................................... Fenoprofen Calcium Capsules USP, EQ 200 mg base ....................... Fenoprofen Calcium Capsules USP, EQ 300 mg base ....................... Fenoprofen Calcium Tablets USP, EQ 600 mg base ........................... Trazodone Hydrochloride (HCl) Tablets USP, 50 mg .......................... Ketoprofen Capsules, 50 mg and 75 mg .............................................. Flurbiprofen Tablets USP, 50 mg and 100 mg ..................................... Pamidronate Disodium for Injection USP, 30 mg/vial and 90 mg/vial .. ANDA 080655 ............... ANDA 083234 ............... Meprobamate Tablets USP, 400 mg .................................................... Glutethimide Tablets, 500 mg ............................................................... ANDA 084156 ............... Pentobarbital Sodium Capsules, 100 mg ............................................. ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA Aminophylline Tables USP, 100 mg ..................................................... Sulfisoxazole Tablets USP, 500 mg ..................................................... Prednisone Tablets USP, 20 mg .......................................................... Sulfamethoxazole Tablets USP, 500 mg .............................................. Amitriptyline HCl Tablets USP, 50 mg .................................................. Amitriptyline HCl Tablets USP, 75 mg .................................................. Amitriptyline HCl Tablets USP, 100 mg ................................................ Cyproheptadine HCl Tablets USP, 4 mg .............................................. Hydroxyzine HCl Tablets USP, 25 mg .................................................. Quinidine Gluconate Extended-Release Tablets USP, 324 mg ........... Prednisone Tablets USP, 10 mg .......................................................... Aurolife Pharma, LLC, 279 Princeton Hightstown Rd., East Windsor, NJ 08520. Do. Upsher-Smith Laboratories, LLC, 301 South Cherokee St., Denver, CO 80223. Aurolife Pharma, LLC. Halsey Drug Co., Inc., 1827 Pacific St., Brooklyn, NY 11233. Cycle Pharmaceuticals, Ltd., c/o Mapi USA, Inc., 2343 Alexandria Dr., Suite 100, Lexington, KY 40504. Do. Do. Aurolife Pharma, LLC. Do. Do. Do. Do. Do. Mustafa Nevzat Ilac San. A.S. (MN Pharmaceuticals), c/o Sagent Pharmaceuticals, Inc., 1901 North Roselle Rd., suite 450, Schaumburg, IL 60195. Aurolife Pharma, LLC. Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr. North, Maple Grove, MN 55369. Warner-Lambert Company, 201 Tabor Rd., Morris Plains, NJ 07950. Halsey Drug Co., Inc. Aurolife Pharma, LLC. Do. Do. Halsey Drug Co., Inc. Do. Do. Do. Do. Aurolife Pharma, LLC. Do. 071129 071133 072394 072395 072396 072484 074024 074448 078300 084674 085628 085813 085844 085925 085926 085927 089057 089117 089894 089983 VerDate Sep<11>2014 ............... ............... ............... ............... ............... ............... ............... ............... ............... ............... ............... 17:37 Apr 17, 2019 Jkt 247001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\18APN1.SGM 18APN1

Agencies

[Federal Register Volume 84, Number 75 (Thursday, April 18, 2019)]
[Notices]
[Pages 16268-16269]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-07816]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

GENERAL SERVICES ADMINISTRATION

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[OMB Control No. 9000-0070; Docket No. 2019-0003; Sequence No. 18]


Information Collection; Payments

AGENCY: Department of Defense (DOD), General Services Administration 
(GSA), and National Aeronautics and Space Administration (NASA).

ACTION: Notice and request for comments.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 and the 
Office of Management and Budget (OMB) regulations, the FAR Council 
invites the public to comment upon a renewal regarding advanced 
payments.

DATES: Submit comments on or before: June 17, 2019.

ADDRESSES: The FAR Council invites interested persons to submit 
comments on this collection by either of the following methods:
     Federal eRulemaking Portal: This website provides the 
ability to type short comments directly into the comment field or 
attach a file for lengthier comments. Go to http://www.regulations.gov 
and follow the instructions on the site.
     Mail: General Services Administration, Regulatory 
Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405. 
ATTN: Ms. Mandell/IC 9000-0070, Payments.
    Instructions: Please submit comments only and cite Information 
Collection 9000-0070, Payments, in all correspondence related to this 
collection. Comments received generally will be posted without change 
to http://www.regulations.gov, including any personal and/or business 
confidential information provided. To confirm receipt of your 
comment(s), please check www.regulations.gov, approximately two-to-
three days after submission to verify posting (except allow 30 days for 
posting of comments submitted by mail). This information collection is 
pending at the FAR Council.

FOR FURTHER INFORMATION CONTACT: Mr. Kevin Funk, Procurement Analyst, 
at telephone 202-357-5805, or via email at [email protected].

SUPPLEMENTARY INFORMATION: 

A. Solicitation of Public Comment

    Written comments and suggestions from the public should address one 
or more of the following four points:
    (1) Evaluate whether the collection of information is necessary for 
the proper performance of the functions of the agency, including 
whether the information will have practical utility;
    (2) Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (3) Enhance the quality, utility, and clarity of the information to 
be collected; and
    (4) Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submission of responses.

[[Page 16269]]

B. Purpose

    Firms performing under Federal contracts must provide adequate 
documentation to support requests for payment under these contracts. 
The documentation may range from a simple invoice to detailed cost 
data. The information is usually submitted once, at the end of the 
contract period or upon delivery of the supplies or services, but could 
be submitted more often depending on the payment schedule established 
under the contract (see Federal Acquisition Regulation (FAR) 52.232-1 
through FAR 52.232-4, FAR 52.232-6, 52.232-7, and 52.232-10).

C. Annual Reporting Burden

    Respondents: 1,724,163.
    Responses per Respondent: 6.
    Annual Responses: 10,344,978.
    Hours per Response: 0.25.
    Total Burden Hours: 2,586,245.
    Obtaining Copies of Proposals: Requesters may obtain a copy of the 
information collection documents from the General Services 
Administration, Regulatory Secretariat Division (MVCB), 1800 F Street 
NW, Washington, DC 20405, at 202-501-4755. Please cite OMB Control No. 
9000-0070, Payments, in all correspondence.

    Dated: April 15, 2019.
Janet Fry,
Director, Federal Acquisition Policy Division, Office of Governmentwide 
Acquisition Policy, Office of Acquisition Policy, Office of 
Governmentwide Policy.
[FR Doc. 2019-07816 Filed 4-17-19; 8:45 am]
 BILLING CODE 6820-EP-P